Skip to main content

Table 4 Brief case history of alveolar soft part sarcomas that responded to immunotherapy

From: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Age Diagnosis Prior Therapies Best response and Duration of response with Immunotherapy
33 Alveolar Soft Part Sunitinib, Pazopanib, cabozantinbi, Vandetanib/Everolimus, Partial Response ×12 months
32 Alveolar Soft Part Cediranib, Sunitinib Partial Response ×8 months